A Phase 4 interventional study of Oxycodone/Naloxone and Codeine/Paracetamol in Osteoarthritis and Back Pain, sponsored by Napp Pharmaceuticals Limited. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-02.
Sponsored by Napp Pharmaceuticals Limited · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Osteoarthritis with a site in United Kingdom — 14 open to participants now, 38 under way, 1 of them phase 3. Osteoarthritis · United Kingdom.
Among the 167 studies in Osteoarthritis with a site in United Kingdom, this one is the 30th largest by enrollment of the 114 interventional ones that give a count, is one of 9 that started in 2009, is one of 16 in phase 4, and was the 23rd registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →14 of the 167 studies in Osteoarthritis with a site in United Kingdom are open now. Recruiting first, the newest first:
Golden Jubilee National Hospital · Sites in United Kingdom
Ages 18+
Eli Lilly and Company · Sites in United Kingdom, United States, Argentina and 10 more countries
Ages 18+
Middlesex University · Sites in United Kingdom
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+
Scarcell Therapeutics S.A.S. · Sites in United Kingdom
Ages 40+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 19 · Phase 4 16
First in 1997; this study’s year is marked. 9 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 108 across the 114 interventional studies, 150 across the 53 observational. Of the 110 that completed or were terminated, 28 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 167 have an industry lead sponsor. The 10 most frequent:
Napp Pharmaceuticals Limited is the lead sponsor of 2 studies on the registry; none are open to participants now.
Napp Pharmaceuticals Limited has 2 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
10 of the studies in Osteoarthritis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550024CrannMedSakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT05889598Loughborough UniversityResistance Exercise Training to Improve Bone and Articular Cartilage Health in Women | 2026-12-31 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 167 studies in Osteoarthritis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare oxycodone/naloxone combination tablet and codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis.
This is a randomised, double-blind, double-dummy, parallel group, 12-week study to assess the efficacy and tolerability of oxycodone/naloxone compared to codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or moderate to severe pain due to OA of the hip and /or knee.
The screening period will be 3 - 7 days duration. If a subject meets all the screening criteria they may enter the Run-in Period.
During the screening period subjects will continue to take their pre-study pain medication.
The run-in period will be 7 - 14 days duration. During the run-in period subjects will continue to take their pre-study pain medication.
Visit 3 will occur at the end of the Run-in Period (7-14 days after Visit 2). To qualify for entry into the treatment period of the study, subjects must have uncontrolled pain as shown by average daily pain scores of >5 on 4 of the last 7 days of the run in period.
Eligible subjects will be randomised to either oxycodone/naloxone or codeine/paracetamol tablets. Subjects will receive double-blind study medication for up to 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxycodone/Naloxone combination
Drug: Oxycodone/Naloxone
Codeine/Paracetamol combination
Drug: Codeine/Paracetamol
Drug pages: Oxycodone · Naloxone
5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
Drug pages: Codeine · Acetaminophen
15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours)
The primary objective was to demonstrate non inferiority of Oxycodone/Naloxone Prolonged Release (OXN PR) compared to codeine/paracetamol in moderate to severe pain as assessed by BS-11 average daily pain scores. The Box Scale-11 is a scale from 0 to 10 (i.e. 0, 1, 2...10), where the subject records their daily pain over the previous 24 hours, by circling the relevant box, where 0 = no pain and 10 = pain as bad as you can imagine. This value is the value recorded at week 12 (average pain over the last 24 hours)
Time frame: Average daily pain over last 24 hours (at Week 12)
Number of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups.
To compare the number of intakes of rescue medication use (ibuprofen) for breakthrough pain between OXN (Oxycodone/Naloxone) and codeine/paracetamol groups. Ibuprofen tablets (400mg up to 3 times per day) were available as rescue medication. This was recorded by the subject in their diary whenever it was taken. The discrepancy in numbers of patients at this stage (between Visit 8 and Visit 9) is due to subject withdrawal during the study. The mean values presented are the "number of intakes of rescue medication" for this period (ie between Visit 8 and Visit 9).
Time frame: Between visit 8 and 9
Patients were recruited in primary and secondary care in the UK from 6 Feb 2009 to 24 Mar 2010
| Milestone | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets |
|---|---|---|
| Started | 124 | 123 |
| Completed | 61 | 74 |
| Not completed | 63 | 49 |
| Withdrew: Adverse event | 32 | 20 |
| Withdrew: Lack of efficacy | 14 | 11 |
| Withdrew: Withdrawal by subject | 11 | 9 |
| Withdrew: Administrative | 5 | 8 |
| Withdrew: Lost to follow-up | 1 | 1 |
The primary objective was to demonstrate non inferiority of Oxycodone/Naloxone Prolonged Release (OXN PR) compared to codeine/paracetamol in moderate to severe pain as assessed by BS-11 average daily pain scores. The Box Scale-11 is a scale from 0 to 10 (i.e. 0, 1, 2...10), where the subject records their daily pain over the previous 24 hours, by circling the relevant box, where 0 = no pain and 10 = pain as bad as you can imagine. This value is the value recorded at week 12 (average pain over the last 24 hours)
| Units on a BS-11 scale at Week 12 | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets |
|---|---|---|
| Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours) | 4.2 ± 2.139 | 4.64 ± 2.046 |
To compare the number of intakes of rescue medication use (ibuprofen) for breakthrough pain between OXN (Oxycodone/Naloxone) and codeine/paracetamol groups. Ibuprofen tablets (400mg up to 3 times per day) were available as rescue medication. This was recorded by the subject in their diary whenever it was taken. The discrepancy in numbers of patients at this stage (between Visit 8 and Visit 9) is due to subject withdrawal during the study. The mean values presented are the "number of intakes of rescue medication" for this period (ie between Visit 8 and Visit 9).
| Number of rescue medication intakes | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets |
|---|---|---|
| Number of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups. | 13.2 ± 23.31 | 9.4 ± 19.94 |
Collected over approximately 3 - 4 months, treatment and outcome. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxycodone/Naloxone Tablets (OXN) | — | 3/124 (2.4%) | 27/124 (21.8%) |
| Codeine/Paracetamol Tablets | — | 4/123 (3.3%) | 32/123 (26%) |
| Event | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets |
|---|---|---|
| Deep vein thrombosisBlood and lymphatic system disorders | 0/124 | 1/123 |
| Head injfuryGeneral disorders | 0/124 | 1/123 |
| Atrial fibrillationCardiac disorders | 0/124 | 1/123 |
| Angina PectorisCardiac disorders | 0/124 | 1/123 |
| joint effusionMusculoskeletal and connective tissue disorders | 1/124 | 0/123 |
| carotid artery stenosisCardiac disorders | 1/124 | 0/123 |
| diarrhoea, rectal haemorrhage, abdominal painGastrointestinal disorders | 1/124 | 0/123 |
| Event | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets |
|---|---|---|
| ConstipationGastrointestinal disorders | 8/124 | 7/123 |
| lower respiratory tract infectionInfections and infestations | 7/124 | 4/123 |
| dyspepsiaGastrointestinal disorders | 4/124 | 6/123 |
| urinary tract infectionInfections and infestations | 2/124 | 5/123 |
| haemorrhoidsGastrointestinal disorders | 0/124 | 4/123 |
| nauseaGastrointestinal disorders | 4/124 | 3/123 |
| bronchitisInfections and infestations | 2/124 | 3/123 |
| Age, Categorical(Participants) | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 66 | 70 | 136 |
| >=65 years | 58 | 53 | 111 |
| Age Continuous(years) | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets | Total |
|---|---|---|---|
| Mean | 64.3 ± 10.53 | 63.9 ± 10.97 | 64.1 ± 10.73 |
| Sex: Female, Male(Participants) | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets | Total |
|---|---|---|---|
| Female | 77 | 81 | 158 |
| Male | 47 | 42 | 89 |
| Region of Enrollment(participants) | Oxycodone/Naloxone Tablets (OXN) | Codeine/Paracetamol Tablets | Total |
|---|---|---|---|
| United Kingdom | 124 | 123 | 247 |
The record gives a start of Feb 2009, a primary completion of Mar 2010 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxycodone · Naloxone
Napp Pharmaceuticals Limited